Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: A phase II, randomized, dose-finding trial.

CONCLUSION: The test sIPV generally demonstrated good safety and immunogenicity. The medium-D antigen dose would be a preferred choice for the further phase III clinical trial in consideration of its high immunogenicity for all serotypes and the satisfying tolerance.
CLINICAL TRIALS REGISTRATION: NCT02985320.
PMID: 30249424 [PubMed - as supplied by publisher]

Source: Vaccine - September 21, 2018 Category: Allergy & Immunology Authors: Chu K, Ying Z, Wang L, Hu Y, Xia J, Chen L, Wang J, Li C, Zhang Q, Gao Q, Hu Y Tags: Vaccine Source Type: research